VXA G2.4 NS
Alternative Names: GII.4 oral vaccine tablet - Vaxart; Monovalent GII.4 tableted vaccine - Vaxart; Norovirus GII.4 vaccine - Vaxart; VXA-G2-4-NS; VXA-G2.4-NSLatest Information Update: 19 Nov 2024
At a glance
- Originator Vaxart
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Norovirus infections
Most Recent Events
- 19 Nov 2024 Phase-I development in Norovirus-infections (Prevention) is ongoing in USA (PO, Tablet)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Norovirus-infections(Prevention) in USA (PO, Tablet)
- 12 Nov 2019 Efficacy data from a phase Ib trial in Norovirus-infections (Prevention) released by Vaxart